

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES OF PARTMENT OF COMMERCAL United States Patent and Trademark Office.

APPLICATION NO	HII NG DAH	FIRST NAMED INVENTOR	ATTORNIA DOCKLENO	CONTINUATION NO	
ny 903-395.	07 10 2001	Keith D. Allen	R-653	9465	
	500 (in p.3.2002				
DELTAGEN, INC.			EXAMINER		
1003 Hamilton Menlo Park, C			WILSON, MICHAEL	ICHAFL C	
			ARTUNII	SABLE ZUMBER	
			16.32	7	
			DATE MAILED 10/03/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office
ADDRESS:
ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

APPLICATION NO.

FILING DATE

FIRST NAMED INVENTOR

ATTY. DOCKET NO.

Γ	٦	EXAMINER	
	AR	RTUNIT	PAPER NUMBER
L	DATE MAIL	ED:	

Please find below and/or attached an Office communication concerning the above identified application.

Commissioner of Patents and Trademarks

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. **The sequences in Fig. 2A do not have a SEQ ID NO**. Applicants must file a "Sequence Listing" accompanied by directions to enter the listing into the specification as an amendment. Applicant also must provide statements regarding sameness and new matter with regards to the CRF and the "Sequence Listing."

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply. Failure to fully comply with the sequence rules in response to the instant office action will be considered non-responsive.

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-0120.

Questions of formal matters can be directed to the patent analyst, Dianiece Jacobs, who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-3388.

the examiner's supervisor. Deborah Reynolds, can be reached on (105) 505 400.

The official fax number for this Group is (703) 308-4242.

Michael C. Wilson

Application No.: <u>09/903395</u>

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: The sequence in Fig. 2A does not have a SEQ ID NO.
lf n	necessary, applicant Must Provide:
X	A substitute computer readable form (CRF) copy of the "Sequence Listing".
X	A substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
x	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	r questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE